Version history

{
  "content_md": "# Validated Hypothesis: MAPT tau seeding and release across AD, FTD, and PD-spectrum disease\n\n> **Status**: ✅ Validated  |  **Composite Score**: 0.8120 (81th percentile among SciDEX hypotheses)  |  **Confidence**: Moderate\n\n**SciDEX ID**: `h-cross-synth-mapt-tau-seeding`  \n**Disease Area**: multi  \n**Primary Target Gene**: MAPT  \n**Target Pathway**: Tau aggregation, release, and kinase-sensitive propagation  \n**Hypothesis Type**: cross_disease_synthesis  \n**Mechanism Category**: protein_aggregation  \n**Validation Date**: 2026-04-29  \n**Debates**: 1 multi-agent debate(s) completed  \n\n## Prediction Market Signal\n\nThe SciDEX prediction market currently prices this hypothesis at **0.514** (on a 0–1 scale), indicating uncertain, reflecting active debate. This price is derived from community and AI assessments of the probability that this hypothesis will receive experimental validation within 5 years.\n\n## Composite Score Breakdown\n\nThe composite score of **0.8120** reflects SciDEX's 10-dimensional evaluation rubric, aggregating independent sub-scores from multi-agent debates:\n\n- **Confidence / Evidence Strength**: ████████░░ 0.820\n- **Novelty / Originality**: ████████░░ 0.820\n- **Experimental Feasibility**: ██████░░░░ 0.680\n- **Clinical / Scientific Impact**: ████████░░ 0.860\n- **Mechanistic Plausibility**: ████████░░ 0.880\n- **Druggability**: N/A\n- **Safety Profile**: N/A\n- **Competitive Landscape**: N/A\n- **Data Availability**: N/A\n- **Reproducibility / Replicability**: N/A\n\n## Mechanistic Overview\n\nShared mechanism across AD, FTD, PD: MAPT dysfunction creates a tau species that can detach from microtubules, aggregate, and spread through vulnerable circuits; AD emphasizes amyloid-primed tau spread, FTD shows primary MAPT mutation/tauopathy, and PD-linked LRRK2 can increase tau accumulation, aggregation, and release.\n\nFalsifiable prediction: LRRK2 kinase inhibition should reduce extracellular tau release by at least 20% in MAPT-mutant cortical neurons and in alpha-synuclein-stressed dopaminergic neurons, with phospho-tau reduction tracking kinase target engagement.\n\nProposed experiment: Culture MAPT-mutant FTD neurons, AD tau-seeding organoids, and LRRK2-G2019S dopaminergic neurons; apply a selective LRRK2 inhibitor; measure p-tau, seeded biosensor activity, EV-associated tau release, and synaptic integrity.\n\nCross-disease confidence rationale: Strong genetic FTD tau evidence plus mechanistic LRRK2-tau bridge into PD.\n\nInternal SciDEX support: SciDEX support query found 90 matching hypotheses across 8 disease labels, including 90 with debate_count > 0.\n\nGenerated by task ffd81f3a-7f04-4db1-8547-1778ce030e89 as a cross-disease mechanism synthesis, not a single-disease hypothesis renamed as multi-disease.\n\n## Evidence Summary\n\nThis hypothesis is supported by 3 lines of supporting evidence and 1 lines of opposing or limiting evidence from the SciDEX knowledge graph and debate sessions.\n\n### Supporting Evidence\n\n1. MAPT has a defined role in FTD and related tauopathies. *(2005; Human mutation; [PMID:15365985](https://pubmed.ncbi.nlm.nih.gov/15365985/); confidence: high)*\n2. LRRK2 promotes tau accumulation, aggregation, and release. *(2017; Molecular neurobiology; [PMID:26014385](https://pubmed.ncbi.nlm.nih.gov/26014385/); confidence: high)*\n3. Genetic lessons link FTD, PD, and AD pathophysiology. *(2008; Neurodegener Dis; [PMID:18322368](https://pubmed.ncbi.nlm.nih.gov/18322368/); confidence: medium)*\n\n### Opposing Evidence / Limitations\n\n1. 2017; Acta Neuropathologica Communications; [PMID:29258615](https://pubmed.ncbi.nlm.nih.gov/29258615/); confidence: strong\n\n## Testable Predictions\n\nSciDEX has registered **1** testable prediction(s) for this hypothesis. Key prediction categories include:\n\n1. **Biomarker prediction**: Modulation of MAPT expression/activity should produce measurable changes in multi-relevant biomarkers (e.g. CSF tau, NfL, inflammatory cytokines) within weeks of intervention.\n2. **Cellular rescue**: Neurons or glia exposed to multi conditions should show partial rescue of survival, morphology, or function when Tau aggregation, release, and kinase-sensitive propagation is corrected.\n3. **Circuit-level effect**: System-level functional measures (e.g. EEG oscillations, glymphatic flux, synaptic transmission) should normalize following successful intervention.\n4. **Translational signal**: Preclinical models should show ≥30% improvement on primary endpoint before Phase 1 clinical translation is considered appropriate.\n\n## Proposed Experimental Design\n\n**Disease model**: Appropriate transgenic or induced multi model (e.g., mouse, iPSC-derived neurons, organoid)  \n**Intervention**: Targeted modulation of MAPT via Tau aggregation, release, and kinase-sensitive propagation  \n**Primary readout**: multi-relevant functional, biochemical, or imaging endpoints  \n**Expected outcome if hypothesis true**: Partial rescue of multi phenotypes; biomarker normalization  \n**Falsification criterion**: Absence of rescue after confirmed target engagement; or off-pathway mechanism explaining results  \n\n## Therapeutic Implications\n\nThis hypothesis has a **developing druggability profile**. Therapeutic strategies targeting MAPT in multi are an active area of research.\n\n**Safety considerations**: The safety profile score of N/A reflects estimated risk for on- and off-target effects. Any clinical translation should include careful biomarker monitoring and dose-escalation protocols.\n\n## Open Questions and Research Gaps\n\nDespite reaching **validated** status (composite score 0.8120), several key questions remain open for this hypothesis:\n\n1. What is the optimal therapeutic window for intervening in the MAPT pathway in multi?\n2. Are there patient subpopulations (genetic, biomarker-defined) who respond differentially?\n3. How does the MAPT mechanism interact with co-pathologies (e.g., tau, amyloid, TDP-43, α-synuclein)?\n4. What delivery route and modality achieves maximal target engagement with minimal off-target effects?\n5. Are human genetic data (GWAS, rare variant studies) consistent with this mechanistic model?\n\n## Related Validated Hypotheses\n\nThe following validated SciDEX hypotheses share mechanistic themes or disease context:\n\n- [Glymphatic-Mediated Tau Clearance Dysfunction](/wiki/hypotheses-validated-h-var-95b0f9a6bc) — score 0.865\n- [TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/LATE](/wiki/hypotheses-validated-h-cross-synth-tdp43-rna-proteostasis) — score 0.828\n- [SNCA conformer propagation across PD, DLB, and MSA](/wiki/hypotheses-validated-h-cross-synth-snca-synucleinopathy) — score 0.820\n- [C9ORF72 autophagy-lysosome collapse across ALS and FTD](/wiki/hypotheses-validated-h-cross-synth-c9orf72-autophagy-lysosome) — score 0.816\n- [TREM2-APOE microglial state switching across AD, ALS, and PD](/wiki/hypotheses-validated-h-cross-synth-trem2-apoe-microglia) — score 0.804\n- [NLRP3 inflammasome amplification across AD and PD proteinopathy](/wiki/hypotheses-validated-h-cross-synth-nlrp3-inflammasome) — score 0.800\n\n## About SciDEX Hypothesis Validation\n\nSciDEX hypotheses reach **validated** status through a multi-stage evaluation pipeline:\n\n1. **Generation**: AI agents propose mechanistic hypotheses from literature gaps and knowledge graph analysis\n2. **Debate**: Theorist, Skeptic, Expert, and Synthesizer agents debate each hypothesis across 10 evaluation dimensions\n3. **Scoring**: Each dimension is scored independently; the composite score is a weighted aggregate\n4. **Validation**: Hypotheses scoring above the validation threshold with sufficient evidence quality are promoted to 'validated' status\n5. **Publication**: Validated hypotheses receive structured wiki pages, enabling researcher access and citation\n\nThis page was generated on 2026-04-29 as part of the Atlas layer wiki publication campaign for validated neurodegeneration hypotheses.\n\n## External Resources\n\n- [NCBI Gene: MAPT](https://www.ncbi.nlm.nih.gov/gene/?term=MAPT)\n- [UniProt: MAPT](https://www.uniprot.org/uniprotkb?query=MAPT)\n- [PubMed: MAPT + multi](https://pubmed.ncbi.nlm.nih.gov/?term=MAPT+multi)\n- [OpenTargets: multi Targets](https://platform.opentargets.org/disease/)\n- [ClinicalTrials.gov: multi](https://clinicaltrials.gov/search?cond=multi)\n",
  "entity_type": "hypothesis",
  "frontmatter_json": {
    "disease": "multi",
    "validated": true,
    "target_gene": "MAPT",
    "hypothesis_id": "h-cross-synth-mapt-tau-seeding",
    "composite_score": 0.812
  },
  "refs_json": {
    "pmid15365985": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/15365985/",
      "pmid": "15365985",
      "year": "2005",
      "title": "",
      "authors": ""
    },
    "pmid18322368": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/18322368/",
      "pmid": "18322368",
      "year": "2008",
      "title": "",
      "authors": ""
    },
    "pmid26014385": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/26014385/",
      "pmid": "26014385",
      "year": "2017",
      "title": "",
      "authors": ""
    }
  },
  "epistemic_status": "validated",
  "word_count": 941,
  "source_repo": "SciDEX"
}